Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
复制标题
DOI：
10.1093/annonc/mdl484
复制
发表时间：
2007-04-01
影响因子：
50.5
通讯作者：
Muggia, F.
中科院分区：
文献类型：
--
作者：
Andreopoulou, E.;Gaiotti, D.;Muggia, F.
背景资料：我们假设，对聚乙二醇脂质体阿霉素（PLD，Caelyx/Doxil）的反应，然后维持是有益的和安全的复发性卵巢cancer.Patients和方法：16例患者接受PLD超过1年复发性卵巢癌（14）或输卵管癌（2）。所有患者对PLD +卡铂（5）或托泊替康（9）双联或PLD单药（2）均有稳定的疾病或更好的反应。每4-8周一次给予30-40 mg/m（2）的PLD维持治疗。这项分析的重点是心脏状态，总体耐受性，和时间recurrent.Results：终止PLD是由于在所有患者的进展。值得注意的是，没有累积骨髓抑制，除了一个例外，临床心脏毒性。该患者在PLD停药后10个月因托泊替康引起的心源性休克和发热并发4级全血细胞减少症住院。7例患者在中位数1680 mg/m2（1180-2460 mg/m2）后继续接受PLD治疗。其中4例患者在维持治疗3-6年后记录复发，发生在延长治疗间隔的情况下。维持PLD后，reinstituted“reinduction”与platinum.Conclusions：PLD似乎是安全的，长期维持卵巢癌，并可能是重要的持续反应。
Background: We hypothesized that a response to pegylated liposomal doxorubicin (PLD, Caelyx/Doxil) followed by maintenance is beneficial and safe in recurrent ovarian cancer.Patients and methods: Sixteen patients have received PLD for more than 1 year for recurrent ovarian (14) or fallopian tube (2) cancer. All had stable disease or better responses to PLD + carboplatin (5) or topotecan (9) doublets or to PLD alone (2). PLD maintenance therapy 30-40 mg/m(2) was given every 4-8 weeks. This analysis focuses on cardiac status, overall tolerance, and time to recurrence.Results: Termination of PLD was due to progression in all patients. Noteworthy was the lack of cumulative myelosuppression and, with one exception, clinical cardiac toxicity. This patient was hospitalized with cardiogenic shock and fever complicating grade 4 pancytopenia from topotecan ten months after discontinuation of PLD. Seven patients continue to receive PLD after a median of 1680 mg/m(2) (1180-2460 mg/m(2)). Four of these had documented relapses after 3-6 years on maintenance occurring in the setting of lengthening of the treatment interval. Maintenance PLD was reinstituted after 'reinduction' with a platinum.Conclusions: PLD appears to be safe as long-term maintenance in ovarian cancer and may be important for a continued response.